Clear-cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer and accounts for ∼60% to 70% of all renal tumours. Despite advances in diagnosis especially for widespread use of abdominal imaging, 20%--30% of all patients are diagnosed with metastatic disease and another 20% of patients undergoing curative nephrectomy will have a relapse and develop metastatic RCC with a poor prognosis during follow-up ([@bib15]). By far, several clinicopathological prognostic models have been commonly used to predict prognosis for postoperative RCC patients, such as the TNM staging system ([@bib4]), the Fuhrman grading system ([@bib8]) and the Mayo Clinic stage, size, grade and necrosis (SSIGN) score ([@bib7]); however, accurate prediction of individual tumour biology remains difficult. It is expected that a combination of specific RCC biomarkers into conventional clinicopathological characteristics will allow better prediction of prognosis ([@bib24]).

Cancer-related inflammation is currently recognised as the seventh hallmark of cancer, which often present with the features of an inflamed tissue, including inflammatory cell infiltration and an activated stroma ([@bib16]). In addition to local inflammatory symptoms, cancer patients frequently present with systemic inflammation responses, including increased peripheral blood cell amounts and decreased haemoglobin and serum albumin levels ([@bib2]). Thus, several circulating blood cell-based prognostic biomarkers have been developed to predict patient outcome in various tumours, such as neutrophil-to-lymphocyte ratio (NLR) ([@bib22]; [@bib11]), platelet-to-lymphocyte ratio (PLR) ([@bib6]; [@bib14]) and lymphocyte-to-monocyte ratio (LMR) ([@bib12]; [@bib25]). Preoperative haemoglobin and serum albumin levels are also reported as prognostic indicators for cancer clinical prognosis ([@bib13]; [@bib20]). These markers are inexpensive to test and routinely performed in clinical setting, and hence potentially provide readily available and objective information to help clinicians to estimate patient outcome. However, there are few reports about the values of these markers, as independent indicators analysed all together and the extent how to integrate them to refine outcome prediction for ccRCC patients.

In this study, we developed a novel prognostic score named systemic inflammation score (SIS) based on preoperative serum albumin and LMR, which were both proven to be independently associated with ccRCC patients outcome adjusting for NLR, PLR, haemoglobin and traditional clinical and pathologic variables, and investigated the correlations of SIS with clinicopathologcal parameters and the prognostic value of SIS in ccRCC patients. Furthermore, a nomogram-combined SIS with TNM stage, Fuhrman grade and lymphovascular invasion was established to predict 3- and 5-year survival for ccRCC patients after surgery.

Patients and methods
====================

Patients
--------

This retrospective study included 441 consecutive patients with ccRCC, who underwent nephrectomy in our institute from 2008 to 2009. The exclusion criteria were as follows: non-ccRCC confirmed histopathologically, a history of previous anti-cancer therapies and other malignancies, bilateral renal cancer, perioperative mortality and preoperative routine laboratory tests unavailable. For each patient, the following clinical and pathologic information was gathered: age at surgery, gender, TNM stage ([@bib4]), Fuhrman grade ([@bib8]), tumour size, tumour necrosis and lymphovascular invasion. Histopathologic review on each of the tumour specimens was performed by a single pathologist to confirm reported pathologic findings. Tumour size was recorded as the longest diameter described in pathologic reports. Tumour necrosis was defined as the presence of microscopic coagulative necrosis. Lymphovascular invasion was defined as the presence of tumour cells within an endothelium-lined space without underlying muscular walls. The presence of nodal metastases was defined by pathologic examinations and the presence of distant metastases was defined according to radiographic findings. The haematological and laboratory parameters were obtained within 1 week before surgery. The SSIGN score was applied to classify patients into three risk levels: 0--3, 4--7 and ⩾8 scores based on tumour stage, size, grade and necrosis ([@bib7]).

Patients with localised RCC were treated with radical or partial nephrectomy. Patients with metastatic RCC were treated with cytoreductive nephrectomy followed by interferon-α-based immunotherapy or tyrosine kinase inhibitors therapy. Patients were followed up postoperatively with physical examination, laboratory studies, chest imaging and abdominal ultrasound or computed tomography every 6 months for the first 2 years and annually thereafter. Follow-up was terminated in January 2015. Overall survival (OS) was defined as the time from surgery to death from all causes or censored at the last follow-up date. The clinicopathological characteristics of patients are shown in [Table 1](#tbl1){ref-type="table"}. Overall survival rates were 91.2% and 85.5% at 3 and 5 years, respectively. After a median follow-up of 66 months (interquartile range, 63--69 months), 65 patients (14.7%) had died from all causes. This study was approved by the Zhongshan hospital\'s Ethics Committee and informed consent was obtained from each patient.

Statistical analysis
--------------------

Analysis was performed with SPSS 21.0 (IBM Corporation, Armonk, NY, USA) and R software version 3.0.2 and the 'rms\' package (R Foundation for Statistical Computing, Vienna, Austria). Pearson *χ*^2^-test or Fisher\'s exact test was used to compare categorical variables and continuous variables were analysed by Wilcoxon rank-sum test or Kruskal--Wallis test. The Kaplan--Meier method with log-rank test was used to compare survival curves. The Cox proportional hazards regression model was applied to perform univariate and multivariate analyses, and those variables that achieved statistical significance in the univariate analysis were entered into the multivariable analysis. We first evaluated these haematological and laboratory markers including NLR, PLR, LMR, haemoglobin and serum albumin as continuous variables, together with traditional clinicopathological variables in the univariate and multivariate analyses, and identified that LMR and serum albumin were independent prognostic factors of OS. Next, the two markers were analysed as categorical variables. Dichotomisation of serum albumin was based on the lower range of normal measurement at 40 g l^−1^ (normal range, 40--55 g l^−1^). Owing to no widely accepted cutpoint of LMR, we used the median value at 4.44 as the cutoff for dichotomisation. The SIS was established based on the combination of different serum albumin and LMR levels. The SIS as well as traditional clinicopathological variables was assessed in the multivariate analysis. A nomogram was created by R software using 'rms\' package. Calibration plots were generated to examine the performance characteristics of the predictive nomogram. The Harrell\'s Concordance index (*C*-index) was used to quantify the predictive accuracy ([@bib10]), which ranges from 0.5 (no predictive power) to 1 (perfect prediction). All statistical tests were two-sided and were performed at a significance level of 0.05.

Results
=======

Associations of LMR, serum albumin and SIS with OS
--------------------------------------------------

Results from the univariate analysis indicated that NLR, PLR, LMR, haemoglobin and serum albumin as continuous variables were prognostic factors of OS as well as TNM stage, Fuhrman grade, tumour size, tumour necrosis and lymphovascular invasion ([Table 2](#tbl2){ref-type="table"}), whereas age at surgery and gender had no prognostic significance for OS. Based on our multivariate analysis, the serum albumin and LMR were independent prognostic factors for OS (HR, 0.909; 95% CI, 0.840--0.985; *P*=0.019; HR, 0.839; 95% CI, 0.705--0.998; *P*=0.047, respectively), together with TNM stage, Fuhrman grade and lymphovascular invasion ([Table 2](#tbl2){ref-type="table"}).

As mentioned above, the continuously coded serum albumin was stratified into \<40 or ⩾40 g l^−1^ and the continuously coded LMR was stratified into \<4.44 or ⩾4.44 for subsequent analyses. Kaplan--Meier analysis indicated that the decreased serum albumin and LMR were both associated with shorter OS (*P*\<0.001 for both) ([Figures 1A and B](#fig1){ref-type="fig"}). To further discriminate patients with different outcome, we combined serum albumin and LMR levels to generate four subgroups. We found significant differences exist among the four subgroups ([Figure 1C](#fig1){ref-type="fig"}). In subgroups of either serum albumin ⩾40 g l^−1^ or LMR ⩾4.44, the OS was quite similar (HR, 1.282; 95% CI, 0.509--3.230; *P*=0.598). Thus, we combined the two subgroups to establish the SIS defined as follows: patients with both decreased serum albumin and decreased LMR (\<40 g l^−1^ and \<4.44, respectively) were assigned score 2; patients with either decreased serum albumin or decreased LMR were assigned score 1 and patients with both elevated serum albumin and elevated LMR (⩾40 g l^−1^ and ⩾4.44, respectively) were assigned score 0. Kaplan--Meier curves showed that high SIS was associated with shorter OS (*P*\<0.001) ([Figure 1D](#fig1){ref-type="fig"}). To investigate further the effect of SIS in stratifying patients with different TNM stages and SSIGN scores, we considered TNM stages I and II as early-stage tumour and TNM stage III and IV as advanced-stage tumour. The SSIGN 0--3 scores, 4--7 scores and ⩾8 scores were grouped as low-risk, intermediate-risk and high-risk, respectively. By Kaplan--Meier analysis, we found that the three subgroups of SIS differed significantly in both early-stage and advanced-stage (*P*=0.002 and *P*\<0.001, respectively) ([Figures 2A and B](#fig2){ref-type="fig"}), and in both SSIGN low-risk level and intermediate/high-risk level (*P*=0.021 and *P*\<0.001, respectively) ([Figures 2C and D](#fig2){ref-type="fig"}).

In the univariate analysis, the SIS had prognostic significance for OS (*P*\<0.001). The multivariate analysis demonstrated the SIS (*P*=0.001), TNM stage (*P*\<0.001), Fuhrman grade (*P*=0.023) and lymphovascular invasion (*P*\<0.001) were independent prognostic factors of OS in ccRCC ([Table 2](#tbl2){ref-type="table"}).

Associations of LMR, serum albumin and SIS with clinicopathological characteristics
-----------------------------------------------------------------------------------

The associations of LMR and serum albumin with clinicopathological characteristics are shown in [Table 3](#tbl3){ref-type="table"}. Decreased serum albumin and LMR were both associated with older age at surgery (*P*\<0.001 for both), high Fuhrman grade (*P*=0.049 and *P*=0.009, respectively), tumour size ⩾5cm (*P*=0.017 and *P*=0.002, respectively), the presence of tumour necrosis (*P*\<0.001 and *P*=0.001, respectively), the presence of lymphovascular invasion (*P*=0.034 and *P*=0.025, respectively) and high SSIGN score (*P*\<0.001 for both). In addition, decrease serum albumin was associated with high TNM stage (*P*\<0.001).

The relationships between the SIS and clinicopathological features are also summarised in [Table 3](#tbl3){ref-type="table"}. High SIS was more likely to have older age at surgery (*P*\<0.001), high TNM stage (*P*\<0.001), high Fuhrman grade (*P*=0.001), large tumour size (*P*=0.001), the presence of tumour necrosis and lymphovascular invasion (*P*\<0.001 and *P*=0.005, respectively), and high SSIGN score (*P*\<0.001) ([Table 3](#tbl3){ref-type="table"}).

Predictive nomogram for OS
--------------------------

To provide a quantitative method for better outcome prediction, we constructed a nomogram that integrated the proven independent prognostic factors consisting of TNM stage, Fuhrman stage, lymphovascular invasion and SIS ([Figure 3A](#fig3){ref-type="fig"}). In this nomogram, a higher total point indicates a worse prognosis. For internal validation, calibration plots of the nomogram predicting 3- and 5-year survival performed well with the ideal model ([Figures 3B and C](#fig3){ref-type="fig"}). The *C*-index of the multivariate prognostic model based on TNM stage, Fuhrman stage and lymphovascular invasion was 0.80 and improved to 0.82 when the SIS (*C*-index 0.71) was incorporated, which showed a better predictive ability of OS than TNM stage (*C*-index 0.68) or SSIGN score (*C*-index 0.78).

Discussion
==========

We investigated clinicopathological characteristics and prognosis of 441 ccRCC patients with haematological and laboratory markers of systemic inflammation responses. We demonstrated that decreased serum albumin and LMR levels before surgery were independent and adverse predictors of OS in multivariate analysis. Furthermore, we created a novel prognostic score named the SIS based on the combination of serum albumin and LMR after dichotomisation, and found that high SIS was associated with high TNM stage, high SSIGN risk level and poor outcome. Together with TNM stage, Fuhrman grade and lymphovascular invasion, the SIS was integrated in a prognostic nomogram that predicted OS with an accuracy of 0.82. The magnitude of the SIS was on the same order as that of Fuhrman grade system. Thus, our study serves as a proof of principal that systemic inflammatory information can provide important prognostic information that augments traditional clinicopathological analysis. It is hoped that additional, prospective and clinical validation studies will be conducted to confirm our findings and further basic research studies will be performed to identify the detailed mechanism that how inflammatory cells and mediators are involved in the pathogenesis and progression of renal cell cancer.

As Virchow originally made links between cancer and inflammation in the nineteenth century, contemporary studies have led to a general acceptance that inflammation has an important role in carcinogenesis ([@bib1]). The hallmarks of cancer-related inflammation consist of the infiltration of inflammatory cells and the production of inflammatory mediators in tumour tissues, tissue remodelling, tissue repair and angiogenesis ([@bib17]). Moreover, inflammation generates not only pro-tumoral microenvironment changes but also systemic changes that can facilitate tumour progression ([@bib2]). Therefore, the complex array of inflammatory cells and inflammatory mediators in tumour microenvironment may be reflected in the peripheral circulation.

Recent studies have shown the prognostic significance of NLR and LMR in postoperative patients with nonmetastatic RCC ([@bib22]; [@bib12]) and that of PLR in patients with advanced RCC ([@bib6]). Moreover, [@bib21] found that preoperative low serum albumin was significantly associated with reduced survival for 369 locoregional RCC patients. Another study for 1828 all-stages RCC patients found that preoperative haemoglobin was a significant predictor of RCC-specific mortality ([@bib13]). However, the prognostic value of integrating these frequently requested haematological and laboratory markers into the traditional clinicopathological features remains obscure in RCC. In our study, we demonstrated that serum albumin and LMR were independent prognostic factors of OS in ccRCC patients. Although NLR, PLR and haemoglobin were significantly associated with survival in univariate analysis, they were not retained as independent indicators in the multivariate model. Furthermore, we created the SIS based on the combination of serum albumin and LMR. We found that both decreased serum albumin and decreased LMR levels (SIS score 2) were associated with advanced tumour stage and poor outcome, and elevated levels of both (SIS score 0) were associated with early tumour stage and favourable outcome, indicating that the SIS could be a more objective marker that reflects the balance between host inflammation and immune response status than indexes such as NLR, PLR and haemoglobin.

As an integrated indicator based on serum albumin and LMR, the biological reason behind the prognostic value of SIS might be elucidated by the function of the albumin, lymphocytes and monocytes. Recent evidence indicates that monocytes can be recruited in tumour tissues and differentiate into tumour-associated macrophages (TAMs) exerting pro-tumoral action ([@bib23]). Lymphocytes can enhance cancer immune-surveillance to inhibit tumour cell proliferation, invasion and metastasis ([@bib3]). Thus, a low circulating lymphocyte amount might be responsible for a weak and insufficient immune response to tumours and an elevated circulating monocyte level may reflect an increased production of TAMs as a marker of high tumour burden. Accordingly, a decrease LMR conveying poor prognosis was observed in a variety of malignancies including RCC ([@bib12]). Serum albumin is known as a negative acute phase protein and is synthesised specially in the liver ([@bib5]). Decreased serum albumin represents not only a malnutrition status but also a sustained systemic inflammation response ([@bib19]), therefore providing significant prognostic information for many types of cancer with or without integration into prognostic systems ([@bib18]; [@bib9]). In agreement with previous findings, we demonstrated that high SIS was an independent predictor of diminished survival for ccRCC patients. Moreover, high SIS was significantly correlated with aggressive tumour biological phenotypes such as advanced tumour stage, high Fuhrman grade, large tumour size and the presence of necrosis and lymphovascular invasion. These results partially reveal complex interactions of elevated systemic inflammation responses and tumour progression. In addition, we found that the SIS could further stratify patients into three risk subgroups in different tumour stages and SSIGN risk levels, suggesting that the SIS might provide additional prognostic information as a complement to the well-established clinicopathological prognostic models.

In tradition, the prediction of prognosis in RCC patients is based on clinical and pathological factors such as TNM stage and SSIGN score. By incorporating the SIS into TNM stages, Fuhrman grade and lymphovascular invasion, a nomogram was constructed and performed well in internal validation. When assessing OS, a higher predictive accuracy of the nomogram can be observed compared with that of TNM stage or SSIGN score. Nonetheless, it needs to be further investigated whether the predictive value of the nomogram is superior to that of SSIGN score for cancer-specific survival (CSS), because the SSIGN score is developed originally with the endpoint of CSS. Meanwhile, the magnitude of the SIS was on the same order as Fuhrman grade. Thus, our study indicates that the SIS can provide additional prognostic information to traditional clinicopathological features. These results may facilitate clinicians to better stratify patients who need adjuvant therapy, intensive postoperative follow-up or participating in clinical trials.

The strength of our study is that the measurement of SIS is based on standard laboratory tests of serum albumin, lymphocyte and monocyte counts, which are routinely applied in clinical practice. However, there are a few limitations in this study. First, owing to the retrospective nature and no external validation, the prognostic significance of the SIS in ccRCC patients remains to be investigated prospectively in other populations and larger cohorts in the future. Second, because C-reactive protein (CRP) is not routinely measured in our clinical practice, we did not add CRP in our analyses. Further studies should estimate the prognostic value of CRP in combination with SIS as well as clinicopathological parameters. Third, because of limited patients with metastasis (*n*=12), we did not specially assess the relationship between the SIS and metastatic disease.

In conclusion, we developed a novel and easily obtained prognostic score named SIS, which was based on preoperative serum albumin and LMR. The SIS served as an independent prognostic factor and should be incorporated into traditional clinical and pathologic variables to complement outcome prediction of ccRCC patients after surgery.
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![**Kaplan--Meier analysis for OS of ccRCC patients according to preoperative serum albumin and LMR.** Kaplan--Meier analysis for OS according to (**A**) preoperative serum albumin, (**B**) preoperative LMR, (**C**) combination of preoperative serum albumin and LMR, and (**D**) SIS.](bjc2015241f1){#fig1}

![**Kaplan--Meier analysis for OS of ccRCC patients according to SIS in different tumour stages and SSIGN scores.** Kaplan--Meier analysis for OS of ccRCC patients according to SIS in (**A**) early-stage (TNM stage I+II), (**B**) advanced-stage (TNM III+IV), (**C**) SSIGN low-risk (score 0--3) and (**D**) SSIGN intermediate/high-risk (score 4--7/score ≥8).](bjc2015241f2){#fig2}

![**Nomogram for predicting 3- and 5-year OS of ccRCC patients after surgery.** (**A**) Nomogram for predicting 3- and 5-year OS of ccRCC patients after surgery. Calibration plot of the nomogram for (**B**) 3-year and (**C**) 5-year survival. The dashed line represents the performance of an ideal nomogram. The blue line indicates the performance of the proposed nomogram. Orange circles are sub-cohorts of the data set; X is the bootstrapped corrected estimate of nomogram with 200 resamples. Vertical bars represent 95% CI. It seems that the nomogram predicts accurately 3- and 5-year OS.](bjc2015241f3){#fig3}

###### Patient and tumour characteristics

  **Characteristics**                **No.**       **%**
  ------------------------------ ---------------- -------
  **Age, years**                                  
  Median (IQR)                     56 (46--63)        
  **Sex**                                         
  Male                                 318         72.1
  Female                               123         27.9
  **T stage**                                     
  T1                                   301         68.3
  T2                                    32          7.3
  T3                                   107         24.3
  T4                                    1           0.2
  **N stage**                                     
  N0                                   434         98.4
  N1                                    7           1.6
  **M stage**                                     
  M0                                   435         98.6
  M1                                    6           1.4
  **TNM stage**                                   
  I                                    297         67.3
  II                                    30          6.8
  III                                  108         24.5
  IV                                    6           1.4
  **Fuhrman grade**                               
  1                                     72         16.3
  2                                    202         45.8
  3                                    106         24.0
  4                                     61         13.8
  **Tumour size, cm**                             
  \<5                                  299         67.8
  ⩾5                                   142         32.2
  **Tumour necrosis**                             
  Absent                               348         78.9
  Present                               93         21.1
  **Lymphovascular invasion**                     
  Absent                               323         73.2
  Present                              118         26.8
  **SSIGN score**                                 
  0--3                                 320         72.6
  4--7                                 105         23.8
  ⩾8                                    16          3.6
  **Haemoglobin, g l**^**−1**^                    
  Median (IQR)                    139 (126--148)      
  **Albumin, g l**^**−1**^                        
  Median (IQR)                     42 (39--44)        
  **NLR**                                         
  Median (IQR)                    2.0 (1.5--2.6)      
  **PLR**                                         
  Median (IQR)                    110 (84--142)       
  **LMR**                                         
  Median (IQR)                    4.4 (3.2--5.8)      

Abbreviations: IQR=interquartile range; LMR=lymphocyte to monocyte ratio; NLR=neutrophil to lymphocyte ratio; No.=number of patients; PLR=platelet to lymphocyte ratio; SSIGN=the Mayo Clinic stage, size, grade, and necrosis.

###### Univariate and multivariate Cox proportional hazards regression analysis for OS

                                            **Univariate**   **Multivariate**[a](#t2-fn2){ref-type="fn"}   **Multivariate**[b](#t2-fn3){ref-type="fn"}                                        
  ---------------------------------------- ---------------- --------------------------------------------- --------------------------------------------- --------- ----------- --------------- ---------
  Age                                           0.185                                                                                                                                              
  Sex                                           0.236                                                                                                                                              
  TNM stage                                    \<0.001                                                                                                   \<0.001                               \<0.001
  I                                                                           Reference                                                                            Reference                       
  II                                                                            1.331                                     0.500--3.541                    0.567      1.277     0.472--3.458     0.630
  III                                                                           2.222                                     1.232--4.008                    0.008      2.348     1.302--4.232     0.005
  IV                                                                           24.483                                    5.197--115.332                  \<0.001    14.644     4.651--46.106   \<0.001
  Fuhrman grade                                \<0.001                                                                                                    0.017                                 0.023
  1                                                                           Reference                                                                            Reference                       
  2                                                                             1.215                                     0.401--3.686                    0.731      1.374     0.455--4.150     0.573
  3                                                                             1.263                                     0.401--3.983                    0.690      1.483     0.477--4.613     0.496
  4                                                                             3.267                                     1.041--10.253                   0.042      3.519     1.133--10.931    0.030
  Tumour size, cm                              \<0.001                                                                                                    0.428                                 0.540
  \<5                                                                         Reference                                                                            Reference                       
  ⩾5                                                                            1.255                                     0.716--2.200                               1.192     0.680--2.091        
  Tumour necrosis                              \<0.001                                                                                                    0.096                                 0.199
  Absent                                                                      Reference                                                                            Reference                       
  Present                                                                       1.621                                     0.918--2.862                               1.449     0.823--2.550        
  LVI                                          \<0.001                                                                                                   \<0.001                               \<0.001
  Absent                                                                      Reference                                                                            Reference                       
  Present                                                                       2.959                                     1.657--5.286                               3.033     1.699--5.414        
  Albumin[c](#t2-fn4){ref-type="fn"}           \<0.001                          0.909                                     0.840--0.985                    0.019                                    
  Haemoglobin[c](#t2-fn4){ref-type="fn"}       \<0.001                          0.993                                     0.977--1.009                    0.406                                    
  LMR[c](#t2-fn4){ref-type="fn"}               \<0.001                          0.839                                     0.705--0.998                    0.047                                    
  PLR[c](#t2-fn4){ref-type="fn"}               \<0.001                          0.997                                     0.994--1.001                    0.138                                    
  NLR[c](#t2-fn4){ref-type="fn"}               \<0.001                          0.971                                     0.838--1.124                    0.691                                    
  SIS                                          \<0.001                                                                                                                                          0.001
  0                                                                                                                                                                Reference                       
  1                                                                                                                                                                  2.109     1.020--4.362     0.044
  2                                                                                                                                                                  4.149     1.980--8.695    \<0.001

Abbreviations: CI=confidence interval; HR=hazard ratio; LMR=lymphocyte to monocyte ratio; LVI=lymphovascular invasion; NLR=neutrophil to lymphocyte ratio; OS=overall survival; PLR=platelet to lymphocyte ratio; SIS=systemic inflammation score.

Adjustment for all variables listed in the table, except for age, sex and SIS.

Adjustment for all variables listed in the table, except for age, sex, albumin, haemoglobin, LMR, PLR and NLR.

Analysed as a continuous variable.

###### Associations of albumin, LMR and SIS with clinicopathological characteristics

                     **Albumin (g/l)**   **LMR**   **SIS**                                                         
  ----------------- ------------------- --------- --------- -------- -------- --------- -------- -------- -------- ---------
  Age, years                                       \<0.001                     \<0.001                              \<0.001
  Median                    58             55                  58       53                 52       58       59         
  IQR                     51--70         45--62              50--67   45--60             44--59   50--66   50--71       
  Sex                                               0.742                       0.032                                0.071
  Male                      83             235                168      150                124      137       57         
  Female                    34             89                  51       72                 61       39       23         
  TNM stage                                        \<0.001                      0.143                               \<0.001
  I                         63             234                141      156                130      130       37         
  II                        12             18                  19       11                 10       9        11         
  III                       37             71                  54       54                 44       37       27         
  IV                         5              1                  5        1                  1        0        5          
  Fuhrman grade                                     0.049                       0.009                                0.001
  1                         15             57                  28       44                 36       29       7          
  2                         47             155                 93      109                 94       76       32         
  3                         31             75                  58       48                 36       51       19         
  4                         24             37                  40       21                 19       20       22         
  Tumour size, cm                                   0.017                       0.002                                0.001
  \<5                       69             230                133      166                139      118       42         
  ⩾5                        48             94                  86       56                 46       58       38         
  Tumour necrosis                                  \<0.001                      0.001                               \<0.001
  Absent                    79             269                158      190                160      139       49         
  Present                   38             55                  61       32                 25       37       31         
  LVI                                               0.034                       0.025                                0.005
  Absent                    77             246                150      173                143      133       47         
  Present                   40             78                  69       49                 42       43       33         
  SSIGN score                                      \<0.001                     \<0.001                              \<0.001
  0--3                      65             255                143      177                149      134       37         
  4--7                      40             65                  61       44                 35       39       31         
  ⩾8                        12              4                  15       1                  1        3        12         

Abbreviations: IQR=interquartile range; LMR=lymphocyte to monocyte ratio; LVI=lymphovascular invasion; SIS=systemic inflammation score; SSIGN=the Mayo Clinic stage, size, grade, and necrosis.
